The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality

BMC Nephrology

Robert Unwin²  David Gustafsson¹ 

[1]Bioscience, CVMD iMED, AstraZeneca R&D Mölndal, Mölndal, Sweden

[2]University College London, UCL Centre for Nephrology, Royal Free Campus, London, UK

关键词: Atherosclerosis;    Cardiovascular events;    Metabolic syndrome;    Type 2 diabetes mellitus;    Congestive heart failure;    Chronic kidney disease;    Hypertension;    Urate;    Uric acid;   

Others  :  1082875
DOI  :  10.1186/1471-2369-14-164

 received in 2013-05-14, accepted in 2013-07-19,  发布年份 2013

【 摘 要 】

Uric acid is the end product of purine metabolism in humans. High levels are causative in gout and urolithiasis. Hyperuricaemia has also been implicated in the pathophysiology of hypertension, chronic kidney disease (CKD), congestive heart failure (CHF), the metabolic syndrome, type 2 diabetes mellitus (T2DM), and atherosclerosis, with or without cardiovascular events. This article briefly reviews uric acid metabolism and summarizes the current literature on hyperuricaemia in cardiovascular disease and related co-morbidities, and emerging treatment options.

【 授权许可】

   
2013 Gustafsson and Unwin; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Choi HK, Mount DB, Reginato AM: Pathogenesis of Gout. Ann Intern Med 2005, 143(7):499-516.
• [2]Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359(17):1811-1821.
• [3]Choi HK, Curhan G: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br Med J 2008, 336:309-312.
• [4]Crittenden DB, Pillinger MH: New therapies for gout. Annu Rev Med 2013, 64:325-337.
• [5]Bobulescu IA, Moe OW: Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 2012, 19(6):358-371.
• [6]Hosomi A, Nakanishi T, Fujita T, Tamai I: Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One 2012, 7(2):e30456.
• [7]Dinour D, Bahn A, Ganon L, Ron R, Geifman Holtzman O, Knecht A, Gafter U, Ruth Rachamimov R, Sela BA, Gerhard Burckhardt G, Holtzman EJ: URAT1 mutations cause renal hypouricaemia type 1 in Iraqi Jews. Nephrol Dial Transplant 2011, 26(7):2175-2181.
• [8]Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, for the EUROSPAN Consortium, et al.: Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009, 5(6):e1000504.
• [9]Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Nalls M, Hernandez D, Arking DE, Boerwinkle E, Grove ML, Li M, Kao WHL, Chonchol M, Haritunians T, Li G, Lumley T, Psaty BM, Shlipak M, Hwang SJ, Larsson MG, O'Donnell CJ, Upadhyay A, van Duijn CM, Hofman A, et al.: Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010, 3(6):523-530.
• [10]Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, Rechavi G, Amariglio N, Ganon L, Sela BA, Bahat H, Goldman M, Weissgarten J, Millar MR, Wright AF, Holtzman EJ: Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010, 21(1):64-72.
• [11]Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O’Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RPS, Brown MJ, Gaffo AL, Pirastu N, Li G, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, Liu X, et al.: Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013, 45(2):145-154.
• [12]Moskowitz JL, Piret SE, Lhotta K, Kitzler TM, Tashman AP, Velez E, Thakker RV, Kotanko P: Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrolin press
• [13]Juraschek SP, Kovell LC, Miller ER III, Gelber AC: Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Sem Arthritis Rheumatism 2013, 42(6):551-561.
• [14]Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote´ F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al.: 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologictherapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64(10):1431-1446.
• [15]Yamanaka H: Japanese guideline for the management of hyperuricemia and gout: Second edition. Nucleosides Nucleotides Nucleic Acids 2011, 30(12):1018-1029.
• [16]Schlesinger N: Difficult-to-treat gouty arthritis. A disease warranting better management. Drugs 2011, 71(11):1413-1439.
• [17]Becker MAH, Ralph Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63. BioMed Central Full Text
• [18]Ryu HJ, Song R, Kim HW, Kim JH, Lee EY, Lee YJ, Song YW, Lee EB: Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 2013, 53(2):211-216.
• [19]Fleischmann R, Shen Z, Yeh L-T, Kerr B, Polvent E, Suster M, Hingorani V, Miner JN, Manhard K, Quart B: Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens [abstract]. Ann Rheum Dis 2011, 70(Suppl. 3):188.
• [20]Kotz J: The gout pipeline crystallizes. Nature Rev Drug Discov 2012, 11(6):425-426.
• [21]Ohno I, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Okabe H, Ichida K, Hosoya T: Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Inter Med 2009, 48(6):415-420.
• [22]Dalbeth N, So A: Hyperuriemia and gout: state of the art and future perspectives. Ann Rheum Dis 2010, 69(10):1738-1743.
• [23]So A, Thorens B: Uric acid transport and disease. J Clin Invest 2010, 120(6):1791-1799.
• [24]Álvarez-Lario B, Macarrón-Vivente J: Is there anything good in uric acid? QJM 2011, 104(12):1015-1024.
• [25]Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38(5):1101-1106.
• [26]Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282(6):F991-F997.
• [27]Grayson PC, Kim SY, LaValley M, Choi HK: Hyperuricemia and incident hypertension: A systemic review and meta-analysis. Arthritis Care Res 2011, 63(1):102-110.
• [28]Feig DI, Johnson RJ: Hyperuricemia in childhood primary hypertension. Hypertension 2003, 42(3):247-252.
• [29]Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. J Am Med Assoc 2008, 300(8):924-932.
• [30]Soletsky B, Feig DI: Uric acid reduction rectifies prehypertension in obese adolescents. Hypertens 2012, 60(5):1148-1156.
• [31]Agarwal V, Hans N, Messerli FH: Effect of allopurinol on blood pressure: A systematic review and meta-analysis. J Clin Hypertens 2013, 16(6):435-442.
• [32]Gois PHF, Souza ERDM: Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Library 2013., 1http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008652.pub2/full webcite
• [33]Choi HK, Soriano LC, Zhang Y, Rodrigues LAG: Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. Br Med J 2012, 344:d8190.
• [34]Nashar K, Fried LF: Hyperuricemia and the Progression of Chronic Kidney Disease: Is uric acid a marker or an independent risk factor. Adv Chronic Kidney Dis 2012, 19(6):386-391.
• [35]Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002, 13(12):2888-2897.
• [36]Johnson RJ, Nakagawa T, Jalal D, Sánchez Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013. in press
• [37]Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47(1):51-59.
• [38]Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5(8):1388-1393.
• [39]Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S: Effect of allopurinol in decreasing proteinuria in Type 2 diabetic patients. Iranian J Kid Dis 2010, 4(2):128-132.
• [40]Shi Y, Chen W, Jalal D, et al.: Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 2012, 35(3):153-160.
• [41]Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ: Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin ii antagonist losartan trial. Hypertension 2011, 58(1):2-7.
• [42]Krishnan E: Gout and the risk for incident heart failure and systolic dysfunction. Br Med J Open 2012, 2(1):e000282.
• [43]Tamariz L, Verma S: Uric acid as a predictor of all-cause mortality in heart failure: A Meta-analysis. Congest Heart Fail 2011, 17(1):25-30.
• [44]Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H, for the JCARE-CARD Investigators: Hyperuricemia predicts adverse outcome in patients with heart failure. Internat J Cardiol 2011, 151(2):143-147.
• [45]Gotsman I, Kern A, Lotan C, Zwas DR: Changes in uric acid levels and allopurinol use in chronic heart failure: Association with improved survival. J Cardiac Failure 2012, 18(9):694-701.
• [46]Filippatos GS, Ahmed MI, Gladden JD, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A: Hyperuricemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Hear J 2011, 32(6):712-720.
• [47]Harzand A, Tamariz L, Hare JM: Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail 2012, 18(3):179-182.
• [48]George J, Carr E, Davies J, Belch JJF, Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering UA. Circulation 2006, 114(23):2508-2516.
• [49]Noman A, Ang DSC, Ogston S, Lang CC, Struthers AD: Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010, 375(9732):2161-2167.
• [50]Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W: Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double- blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010, 3(1):73-81.
• [51]Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006, 55(10):1293-1301.
• [52]Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H: Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009, 32(9):1737-1742.
• [53]Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008, 31(2):361-362.
• [54]Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42(3):474-480.
• [55]Kanellis J, Kang DH: Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25(1):39.42.
• [56]Li C, Hsieh MC, Chang SJ: Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 2013, 25(2):210-216.
• [57]Facchini F, Chen YD, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. J Am Med Assoc 1991, 266(21):3008-3011.
• [58]Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciaciaro D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol 1995, 268(1):E1-E5.
• [59]Muscelli E, Natali A, Bianchi S, Bigazzi S, Quinones Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996, 9(8):746-752.
• [60]Bibert S, Hess SK, Firsov D, Thorens B, Geering K, Horisberger JD, Bonny O: Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol 2009, 297(3):F612-619.
• [61]Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H: Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008, 283(5):26834-26838.
• [62]Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ: Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006, 17(7):1791-1795.
• [63]Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007, 293(2):C584-596.
• [64]Shafiu M, Johnson RJ, Turner ST, Langaee T, Gong Y, Chapman AB, Gums JG, Johnson JA: Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res 2012, 35(6):477-482.
• [65]Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY: Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011, 60(4):1258-1269.
• [66]Brymora A, Flisinski M, Johnson RJ, Goszka G, Stefanska Manitius J: Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 2012, 27(2):608-612.
• [67]Mangge H, Zelzer S, Puerstner P, Schnedl WJ, Reeves G, Postolache TT, Weghuber D: Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity 2013, 21(1):E71-E77.
• [68]Petta S, Camma CD, Cabibi D, Di Marco V, Craxi A: Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Therapeut 2011, 24(7):757-766.
• [69]Petta S, Macaluso SF, Cammà C, Di Marco V, Cabibi D, Craxì A: Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int 2012, 32(9):1443-1450.
• [70]Bell DSH: Beware of the low urine pH-the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes. Diabetes Obes Metab 2012, 14(4):299-303.
• [71]Culleton BF, Larson MG, Kannel WB: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131(1):7-13.
• [72]Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Rheum 2010, 62(2):170-180.
• [73]Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Rheum 2009, 61(7):885-892.
• [74]Rablink TJ, Luscher TF: Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 2006, 26(2):267-271.
• [75]Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR: Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Therap 2012, 30(4):217-226.
• [76]Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD: Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011, 58(8):820-828.
• [77]Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, Dogdu O, Kilinc Y, Zencir C, Akpek M, Ozdogru I, Oguzhan Kalay AN: Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 2011, 20(3):182-187.
• [78]Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, López R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, Lavandero S: Xanthine-oxidase inhibitors and statins in chronic heart failure: Effects on vascular and functional parameters. J Heart Lung Transpl 2011, 30(4):408-413.
• [79]Waring WS, McKnight JA, Webb DJ: Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia 2007, 50(12):2572-2579.